Although there is no evidence that the incidence of congenital anomalies in offspring of patients taking< Zocord > or another closely related HMG-CoA reductase inhibitor differs from that observed in the general population, maternal treatment with < Zocord > may reduce the foetal levels of mevalonate which is a precursor of cholesterol biosynthesis.